BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38529551)

  • 21. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
    PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
    Szpechcinski A; Florczuk M; Duk K; Zdral A; Rudzinski S; Bryl M; Czyzewicz G; Rudzinski P; Kupis W; Wojda E; Giedronowicz D; Langfort R; Barinow-Wojewodzki A; Orlowski T; Chorostowska-Wynimko J
    Cell Mol Life Sci; 2019 Sep; 76(18):3641-3656. PubMed ID: 30953094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
    Diao Z; Han Y; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 27. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients.
    Peng H; Lu L; Zhou Z; Liu J; Zhang D; Nan K; Zhao X; Li F; Tian L; Dong H; Yao Y
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31739500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumour DNA in
    Cabanero M; Tsao MS
    Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
    Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
    Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
    Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
    J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.
    Hu W; Yang Y; Zhang L; Yin J; Huang J; Huang L; Gu H; Jiang G; Fang J
    Cancer Med; 2017 May; 6(5):962-974. PubMed ID: 28382702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
    Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.